GlassScriptPhysician profile
Meagan E Miller
NPI 1134577422
$1,805.53
in general payments reported to CMS, 2019-2025
30 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $195 · 2022: $280 · 2023: $275 · 2024: $718 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.62 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $213.51 | 2021-2023 | Tukysa |
| Pfizer INC. | $213.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $148.22 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $131.07 | 2022-2023 | Lumakras |
| Epizyme, INC. | $99.99 | 2021 | |
| Daiichi Sankyo INC. | $96.00 | 2024 | Enhertu |
| Novartis Pharmaceuticals Corporation | $87.96 | 2023-2025 | |
| Genzyme Corporation | $69.69 | 2023-2025 | |
| Eisai INC. | $69.34 | 2023-2025 | |
| Lilly USA, LLC | $48.95 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $43.96 | 2024-2025 | Zejula |
| Astellas Pharma US INC | $41.26 | 2024-2025 | Padcev, Veozah |
| Sun Pharmaceutical Industries INC. | $40.74 | 2024 | |
| Tempus Ai, INC | $33.47 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $28.84 | 2024 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $26.58 | 2024 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $22.03 | 2025 | Xalkori, Lorbrena, Braftovi |
| Pharmaessentia USA Corporation | $21.91 | 2023 | Besremi |
| Janssen Biotech, INC. | $21.26 | 2024 | Rybrevant |
| Taiho Oncology, INC. | $18.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.18 | 2025 | |
| Genentech USA, INC. | $17.80 | 2024 | Rozlytrek, Tecentriq, Alecensa |
| Astrazeneca Pharmaceuticals LP | $17.34 | 2025 | Lynparza |
| E.R. Squibb & Sons, L.L.C. | $17.08 | 2025 | Opdualag |
| Pharmacosmos Therapeutics INC. | $16.37 | 2023 | Monoferric |
| Morphosys, US INC. | $16.24 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $16.15 | 2024 | Beleodaq |
| Janssen Pharmaceuticals, INC | $15.79 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $13.67 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.